Predictive markers in breast cancer - the future

被引：24

作者：

Faratian, D. ^{[1
]}

Bartlett, J. ^{[1
]}

机构：

[1] Edinburgh Canc Res Ctr, Endocrine Canc Grp, Edinburgh EH4 2XR, Midlothian, Scotland

来源：

HISTOPATHOLOGY | 2008年 / 52卷 / 01期

关键词：

clinical trial; predictive biomarkers; PTEN; RTK inhibitors; topoisomerase II; trastuzumab;

D O I：

10.1111/j.1365-2559.2007.02896.x

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

The published literature is awash with examples of new tissue biomarkers promising to predict responses to therapy in breast cancer patients. However, few, if any, of these progress from the laboratory to the clinic. In this review we discuss some of the reasons for this, illustrating our discussion with a selection of biomarkers which are in development and which may be candidates for clinical application within the next few years (topoisomerase II alpha, epidermal growth factor receptor, AKT, phosphatase and tensin homologue). In particular, we explore how our ever increasing knowledge of molecular and pathway biology is facilitating hypothesis-driven biomarker discovery, and the statistical considerations which need to be addressed in order to validate new candidate biomarkers adequately.

引用

页码：91 / 98

页数：8

共 65 条

[41] HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer [J].

Moliterni, A ;

Ménard, S ;

Valagussa, P ;

Biganzoli, E ;

Boracchi, P ;

Balsari, A ;

Casalini, P ;

Tomasic, G ;

Marubini, E ;

Pilotti, S ;

Bonadonna, G .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (03) :458-462

[42]

Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022

[43] Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma [J].

Nielsen, TO ;

Hsu, FD ;

Jensen, K ;

Cheang, M ;

Karaca, G ;

Hu, ZY ;

Hernandez-Boussard, T ;

Livasy, C ;

Cowan, D ;

Dressler, L ;

Akslen, LA ;

Ragaz, J ;

Gown, AM ;

Gilks, CB ;

van de Rijn, MV ;

Perou, CM .

CLINICAL CANCER RESEARCH, 2004, 10 (16) :5367-5374

[44] HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15 [J].

Paik, S ;

Bryant, J ;

Tan-Chiu, E ;

Yothers, G ;

Park, C ;

Wickerham, DL ;

Wolmark, N .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (24) :1991-1998

[45] EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib [J].

Pao, W ;

Miller, V ;

Zakowski, M ;

Doherty, J ;

Politi, K ;

Sarkaria, I ;

Singh, B ;

Heelan, R ;

Rusch, V ;

Fulton, L ;

Mardis, E ;

Kupfer, D ;

Wilson, R ;

Kris, M ;

Varmus, H .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (36) :13306-13311

[46] Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer [J].

Parra, HS ;

Cavina, R ;

Latteri, F ;

Zucali, PA ;

Campagnoli, E ;

Morenghi, E ;

Grimaldi, GC ;

Roncalli, M ;

Santoro, A .

BRITISH JOURNAL OF CANCER, 2004, 91 (02) :208-212

[47] Molecular portraits of human breast tumours [J].

Perou, CM ;

Sorlie, T ;

Eisen, MB ;

van de Rijn, M ;

Jeffrey, SS ;

Rees, CA ;

Pollack, JR ;

Ross, DT ;

Johnsen, H ;

Akslen, LA ;

Fluge, O ;

Pergamenschikov, A ;

Williams, C ;

Zhu, SX ;

Lonning, PE ;

Borresen-Dale, AL ;

Brown, PO ;

Botstein, D .

NATURE, 2000, 406 (6797) :747-752

[48] Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer [J].

Poole, Christopher J. ;

Earl, Helena M. ;

Hiller, Louise ;

Dunn, Janet A. ;

Bathers, Sarah ;

Grieve, Robert J. ;

Spooner, David A. ;

Agrawal, Rajiv K. ;

Fernando, Indrajit N. ;

Brunt, A. Murray ;

O'Reilly, Susan M. ;

Crawford, S. Michael ;

Rea, Daniel W. ;

Simmonds, Peter ;

Mansi, Janine L. ;

Stanley, Andrew ;

Harvey, Peter ;

McAdam, Karen ;

Foster, Liz ;

Leonard, Robert C. F. ;

Twelves, Christopher J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (18) :1851-1862

[49] HER2 and responsiveness of breast cancer to adjuvant chemotherapy [J].

Pritchard, KI ;

Shepherd, LE ;

O'Malley, FP ;

Andrulis, IL ;

Tu, DS ;

Bramwell, VH ;

Levine, MN .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (20) :2103-2111

[50] Clinical value of epidermal growth factor receptor expression in primary breast cancer [J].

Rampaul, RS ;

Pinder, SE ;

Nicholson, RI ;

Gullick, WJ ;

Robertson, JF ;

Ellis, IO .

ADVANCES IN ANATOMIC PATHOLOGY, 2005, 12 (05) :271-273

← 1 2 3 4 5 6 7 →